Date: May 26, 2026

Financial Performance Summary

AstraZeneca Pharma India Limited announced its audited financial results for the quarter and financial year ended March 31, 2026.

Full Year FY 2025-2026 Performance (Apr '25-Mar '26):

  • Total Revenue from Operations: INR 22,755.8 Million
  • Profit before exceptional item and tax: INR 2,574.5 Million
  • Profit after exceptional item and tax: INR 1,875.2 Million

Q4 FY 2025-2026 Performance (Jan-Mar '26):

  • Total Revenue from Operations: INR 5,786.1 Million
  • Profit before exceptional item and tax: INR 592.2 Million
  • Profit after exceptional item and tax: INR 448.8 Million

The company delivered a 33% year-on-year growth in total revenue.

Therapy Area-wise Performance

The revenue breakdown by therapy area for FY 2025-26 was:

  • Oncology Biopharmaceuticals: INR 16,100.9 Million
  • Biopharmaceuticals (CVRM, R&I and V&I): INR 5,243.2 Million
  • Rare Disease: INR 214.6 Million

Key Business Milestones and Regulatory Approvals

The company achieved 11 new regulatory approvals from the Central Drugs Standard Control Organisation (CDSCO) in FY 2025-26:

Durvalumab Approvals:

  • Endometrial Cancer: Approved for first-line treatment of adults with primary advanced or recurrent endometrial cancer in combination with carboplatin and paclitaxel, followed by maintenance with Durvalumab and Olaparib for pMMR cancers.
  • Muscle Invasive Bladder Cancer (MIBC): Approved as adjuvant treatment following radical cystectomy for adult patients.
  • Gastric Cancer: Approved in January 2026 in combination with FLOT chemotherapy as perioperative treatment for adults with resectable gastric or gastroesophageal junction adenocarcinoma.
  • Liver Cancer: Durvalumab plus tremelimumab received expanded approval in March 2026 for first-line treatment of unresectable hepatocellular carcinoma.

Other Key Approvals and Launches:

  • Eculizumab: Launched as the first anti-complement therapy approved in India for the treatment of atypical Haemolytic Uremic Syndrome (aHUS) and Paroxysmal Nocturnal Hemoglobinuria (PNH).
  • Osimertinib: Received approval for an additional indication in combination with pemetrexed and platinum-based chemotherapy for first-line treatment of locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 (L858R) mutations. Also gained approval as monotherapy for locally advanced, unresectable (stage III) NSCLC with the same mutations.
  • Trastuzumab deruxtecan: Approved for an additional indication in HER2-low and HER2-ultralow metastatic breast cancer patients who have received at least one endocrine therapy.
  • Benralizumab: Approved for an additional indication as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA).
  • Sodium Zirconium Cyclosilicate (5g/10g): Received CDSCO permission for import and sale in India for the management of hyperkalaemia in adults, in partnership with Sun Pharma.

Management Commentary

Bhavana Agrawal, Chief Financial Officer & Director: Commented that FY 2025-26 was a year of strong and consistent growth, underpinned by the resilience of the business, the strength of the science-led portfolio, and disciplined execution. The performance reflects commercial momentum and a commitment to creating sustainable value.

Praveen Rao Akkinepally, Managing Director: Stated that science is at the heart of everything the company does. The performance reflects progress in accelerating the delivery of innovative medicines and advancing the ambition to transform patient outcomes in India. The company remains focused on addressing unmet medical needs.

Recognitions

The company received several awards in FY 2025-26:

  • Pharma Company of the Year at ET RePharma Awards
  • Medical Excellence Award for Rare Disease at OPPI India
  • Recognised as Top Employer India 2025
  • Marketing Excellence Award for Hyperkalaemia & Kidney Care, Biopharmaceuticals at OPPI India
  • OPPI Medical Excellence Award 2025 for Medical Affairs, Regulatory Excellence, and Clinical Trials
  • 1st Place in 2025 SAS Customer Recognition Awards for innovative use of Real-World Data
  • ET HRWorld EX Awards 2025 for Exceptional Employee Experience (Large Scale)
  • Excellence in Precision Biopharma Solutions at the VOH National Healthcare Awards 2025

Company Overview

AstraZeneca Pharma India Limited is a science-led biopharmaceutical company focused on prescription medicines in four therapy areas: Oncology, Cardiovascular, Renal & Metabolism, Respiratory, and Rare Disease. The company completed 45 years in India, is headquartered in Bengaluru, and has over 600 employees.